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Abstract
We have demonstrated that the signal transducer and activator
of transcription 3 (STAT3) protects from cholestatic liver in-
jury. Specific ablation of STAT3 in hepatocytes and
cholangiocytes (STAT3Δhc) aggravated liver damage and fi-
brosis in the Mdr2−/− (multidrug resistance 2) mouse model
for cholestatic disease. Upregulation of bile acid biosynthesis
genes and downregulation of epidermal growth factor receptor
(EGFR) expression were observed in STAT3Δhc Mdr2−/−mice
but the functional consequences of these processes in chole-
static liver injury remained unclear. Here, we show normal
canalicular architecture and bile flow but increased amounts
of bile acids in the bile of STAT3Δhc Mdr2−/−mice. Moreover,
STAT3-deficient hepatocytes displayed increased sensitivity
to bile acid-induced apoptosis in vitro. Since EGFR signaling
has been reported to protect hepatocytes from bile acid-
induced apoptosis, we generated mice with hepatocyte/
cholangiocyte-specific ablation of EGFR (EGFRΔhc) and
crossed them to Mdr2−/− mice. Importantly, deletion of
EGFR phenocopied deletion of STAT3 and led to aggravated
liver damage, liver fibrosis, and hyperproliferation of K19+
cholangiocytes. Our data demonstrate hepatoprotective func-
tions of the STAT3-EGFR signaling axis in cholestatic liver
disease.
Key message
& STAT3 is a negative regulator of bile acid biosynthesis.
& STAT3 protects from bile acid-induced apoptosis and reg-
ulates EGFR expression.
& EGFR signaling protects from cholestatic liver injury and
fibrosis.
Keywords Epidermal growth factor receptor EGFR . Signal
transducer and activator of transcription 3 STAT3 .
Cholestasis . Bile acids . Liver injury . Hepatocyte apoptosis
Introduction
Chronic cholestatic liver diseases are characterized by re-
tention of bile acids in the liver which results in alter-
ations of hepatobiliary bile acid transport and enzyme
activities participating in bile acid biosynthesis.
Hydrophobic bile acids are particularly toxic and promote
cholangiocyte/hepatocyte damage, liver fibrosis, cirrhosis,
and formation of hepatocellular carcinoma (HCC) under
cholestatic conditions [1–3]. Deposition of collagen and
other extracellular matrix components is an orchestrated
event in cholestatic liver fibrosis and involves several cell
types including Kupffer cells and stellate cells. The latter
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are activated by inflammatory cytokines and responsible
for deposi t ion of col lagen together with porta l
myofibroblasts [2]. Despite profound knowledge about
cell types that promote cholestatic liver fibrosis and cir-
rhosis, little is known about hepatoprotective factors that
modulate initial events of cholestatic liver injury. The
transcription factor STAT3 is required for liver regenera-
tion and hepatoprotection in various chronic liver diseases
[4]. STAT3 is mainly activated by IL-6 (interleukin 6) and
IL-22 in hepatocytes. These cytokines bind to gp130 (gly-
coprotein 130) receptors and promote phosphorylation of
STAT3 at tyrosine-705 (pY-STAT3) via Janus kinases
(JAKs), STAT3 dimerization, and nuclear translocation
[4].
Hepatoprotective functions of STAT3 signaling in cho-
lestatic liver disease have been investigated in mice lack-
ing STAT3, IL-6, gp130, or express pathway specific
gp130 mutants. Bile duct ligation, cholic acid feeding,
and genetic deletion of the Mdr2 gene (Mdr2−/−) resulted
in aggravated cholestatic liver injury and fibrosis in
hepatocyte-specific STAT3 knock-out mice and IL-6−/−
mice [5, 6]. Moreover, mice with hepatocyte-specific de-
letion of gp130 (gp130hepa) displayed aggravated liver
fibrosis and collagen deposition after DDC (3,5-
diethoxycarbonyl-1,4-dihydrocollidine) feeding which is
a chemical model for sclerosing cholangitis [7]. The use
of specific gp130 knock-in mutant alleles that lack either
the region for STAT3 activation (gp130ΔhepaSTAT) or carry
a Y757F mutation that impedes activation of the Ras/
MAPK pathway (gp130ΔhepaRas) [7] demonstrated that
the hepatoprotective activity of gp130 signaling was due
to gp130-mediated STAT3 activation.
Several cellular and molecular mechanisms might ac-
count for the hepatoprotective activity of IL-6/gp130/
STAT3 signaling in cholestatic liver injury [4]. We dem-
onstrated that enzymes for bile acid biosynthesis are up-
regulated in livers of Mdr2−/− mice, lacking STAT3 in
hepatocytes and cholangiocytes (STAT3Δhc) [6], which
might result in increased production of toxic bile and ag-
gravated cholestatic liver damage. Moreover, expression
of epidermal growth factor receptor (EGFR) was down-
regulated in livers of STAT3Δhc Mdr2−/− mice. EGFR sig-
naling protects hepatocytes from bile acid-induced apo-
ptosis which was demonstrated in vitro with hepatocytes
harboring a dominant negative ERBB1 allele. A similar
protective effect was observed after pretreatment of hepa-
tocytes with the EGFR antagonist Iressa [8–11].
Here, we employed Mdr2−/− mice to functionally test
the hepatoprotective function of EGFR signaling in bile
acid-induced liver injury and fibrosis. Importantly, condi-
t ional inactivation of EGFR in hepatocytes and
cholangiocytes (EGFRΔhc) of Mdr2−/− mice led to severe
jaundice and strongly aggravated liver damage and
fibrosis. These data suggest a pivotal hepatoprotective
function for EGFR signaling in cholestatic liver disease.
Methods
Mice
STAT3Δhc mice were generated by crossing mice carrying
floxed alleles of STAT3 [12] to AlfpCre transgenic mice
[13]. Furthermore, mice harboring floxed alleles of EGFR
[14] were crossed to AlfpCre transgenic mice. Resulting
AlfpCre EGFRflox/flox (EGFRΔhc) mice were bred with
Mdr2−/− mice [15] to generate EGFRΔhc Mdr2−/− mice.
Blood sera, bile, and liver tissue of a 7 week old male
mouse were used for analyses. All mouse experiments
were performed in accordance with Austrian and
European laws and with the general regulations specified
by the Good Science Practice guidelines of the Medical
University of Vienna.
Histology and immunohistochemistry
Bile canaliculi, sinusoids, and central veins were visual-
ized by immunofluorescence using a combination of anti-
bodies directed against DPPIV/CD26, glutamine synthe-
tase (GS), and secondary fluorochrome coupled antibod-
ies as described previously [16]. For other stainings, livers
we r e f o rma l i n - f i x e d and p a r a f f i n - embedded .
Hematoxylin/eosin and Sirius-red stainings were per-
f o r m e d a c c o r d i n g t o s t a n d a r d p r o c e d u r e s .
Immunohistochemical stainings were performed with an-
t ibodies for CD3 (His tocom, RM-9107) , F4/80
(eBioscience, 14–4801-82), Ki67 (Novocastra, NCL-
Ki67p), and K19 (monoclonal rat anti-Troma-III antibody
provided by Rolf Kemler). For detection of apoptotic
cells, ApopTag® Peroxidase in Situ Apoptosis Detection
Kit (Millipore, S7100) was used.
Cell culture, MTT assay, and caspase 3/8 activity assay
Primary hepatocytes were isolated by collagenase liver
perfusion using perfusion buffer (17,701–038, Applied
Biosystems) and subsequent digestion buffer (17,703–
034, Applied Biosystems). Cells were seeded in collagen
coated wells and kept in Williams E medium (12,551–
032, Applied Biosystems) overnight. On the following
day, primary hepatocytes were treated with different con-
centrations of bile acids. Immortalized hepatocytes were
cultured in RPMI supplemented with 80 ng/ml TGF-alpha
(T7924, Sigma), 60 ng/ml IGF-II (I2526, Sigma), and
2.8 μM insulin (Novo Nordisk). Before stimulation with
IL-6 (40 ng/ml, ImmunoTools, 12,340,065), immortalized
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hepatocytes were cultured over night without growth fac-
tors and treated with IL-6 for 2 h and 4 h. For viability
testing, cells were incubated for 3 h at 37 °C with 1 mg/ml
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide). The plates were dried and the crystals were
dissolved. Absorbance was measured at 550 nm to assess
cell viability. For detection of active caspases, cells were
lysed and incubated with fluorescent substrates specific
for caspase 3 (Ac-DEVD-AFC, ALX-260-032, Enzo
Life Sciences) or caspase 8 (Ac-LETD-AFC, ALX-260-118,
Enzo Life Sciences) for 1 h at 37 °C. Fluorescence
was measured at an excitation wavelength of 400 nm and
an emission wavelength of 505 nm.
PCR for genotyping
Genotyping was performed by PCR with primers 5′-
gcgtctgactctacaacc-3′, 5′-agcctcatccttaggtact-3′ and 5′-
gac tg tga t aacc t t cag tg -3 ′ fo r f l oxed STAT3 , 5 ′ -
aagtttaagaaaccccgctctact-3′, 5′-gcctgtgtccgggtctcgtcg-3′
and 5′-caaccagtgcacctagcctggc-3′ for floxed EGFR, 5′-
cggtcgatgcaacgagtgatgagg-3′ and 5′-ccagagacggaaat-3′




Total RNA was isolated with TRIzol (Life Technologies,
15596-018) and reverse transcribed with QuantiTect
Reverse Transcription Kit (Qiagen, 205313). qPCR was
performed using Fast SYBR Green Mastermix (Thermo
Fisher Scientific, 4385616) and an Applied Biosystems
7500 Fast Real Time PCR System with primers 5′-
caccctcaagagcctgagtc-3′ and 5′-gttcgggctgatgtaccagt-3′
for COL1, 5 ′ -caggtgaacccggcaagaacg-3 ′ and 5 ′-
g g g g a c c a g g g c g a c c a c t - 3 ′ f o r C O L 3 , 5 ′ -
t c c t c t t g t t g c t a t c a c t g a t a g c t t - 3 ′ a n d 5 ′ -
c g c t g g t a t a a g g t g g t c t c g t t - 3 ′ f o r T IMP 1 , 5 ′ -
ccagaagaagagcctgaacca-3′ and 5′-gtccatccagaggcactcatc-
3 ′ for TIMP2, 5 ′-agaggtcacccgcgtgctaa-3 ′ and 5 ′-
t c c c g a a t g t c t g a c g t a t t g a - 3 ′ f o r T G FB 1 , 5 ′ -
tcgtccgctttgatgtctca-3′ and 5′-aaatctcgcctcgagctcttc-3′ for
TGFB2 , 5 ′ - ccgaggac t a t gaccggga t aa -3 ′ and 5 ′ -
c t t g t t g c c c a g g a a a g t g a a g - 3 ′ f o r MMP 2 , 5 ′ -
atcccaccaaagtgagaacg-3′ and 5′-taatttccctccccggttac-3′ for
CTGF, 5 ′ - aa tcccaggaccaac ta tggcagc-3 ′ and 5 ′ -
g a g g c a a a c t t c t g t t c c a a t g g - 3 ′ f o r E G FR , 5 ′ -
tgtttgtgatgggtgtg-3 ′ and 5 ′-tacttggcaggtttctc-3 ′ for
GAPDH. The expression levels of transcripts were calcu-
lated with the comparative CT (threshold concentration)
method. The individual RNA levels were normalized for
GAPDH and are depicted as relative expression levels.
Serum measurements
Serum levels of bilirubin, alanine aminotransferase (ALT),
and alkaline phosphatase (ALP) were measured using the
Reflotron® System (Roche Applied Science).
Bile flow measurement and bile composition
To measure bile flow, mice were anesthetised and kept on a
heating plate during the experiment. The common bile duct
was ligated using a string. The gall bladder was punctuated
and a cannula was inserted and fixed. The bile was collected in
a tube for 30 min, and afterwards the liver weight was mea-
sured. Bile acids in the bile were analyzed by isotope-dilution
gas chromatography-mass spectrometry (GCMS) as described
previously [17].
Hydroxyproline
Livers were homogenized and hepatic hydroxyproline levels
were measured as described previously [18].
Western blot
Protein lysates were obtained according to standard pro-
cedures and analyzed by Western blot with antibodies for
P-STAT3 (Cell Signaling, 9145) and β-actin (Sigma,
A5316).
Statistics
Significant differences were calculated with GraphPad
Prism 5. Comparisons of the two groups were analyzed
with unpaired t test or Mann-Whitney test. For more than
two groups One-Way Analysis of Variance (ANOVA) and
Bonferroni post test or Kruskal Wallis, and Dunns post
test were used. Significant differences between experi-
mental groups are stated as: *p < 0.05, **p < 0.01, or
***p < 0.001.
Results
STAT3 inhibits bile acid production
We have recently shown that STAT3 is a negative regu-
lator of bile acid biosynthesis gene expression [6].
Consistent with increased mRNA expression of Cyp7a1
(cytochrome P450 family 7, subfamily A, polypeptide 1)
and Cyp27a1 [6] significantly elevated bile acid concen-
trations were observed in bile collected of STAT3Δhc
(AlfpCre STAT3flox/flox) mice (Fig. 1a). GCMS (gas
chromatography-mass spectrometry) analysis of bile
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demonstrated no substantial difference of relative bile
acid composition between STAT3flox/flox and STAT3Δhc
m i c e (F i g . 1b ) , e x c ep t f o r i n c r e a s ed UDCA
(ursodeoxycholic acid) levels in STAT3Δhc mice. UDCA
is a primary bile acid in mice, although its synthesis is
not clearly defined [17]. No difference was observed in
bile flow (Fig. 1c) which was consistent with normal
morphology of bile canaliculi (Fig. 1d). These data indi-
cate that STAT3 inhibits production of excessive amounts
of bile acids.
Fig. 1 Increased bile acid
concentration in the bile of
STAT3Δhc mice. a The total
amount of bile acids was
measured in collected bile of
STAT3flox/flox and STAT3Δhc
mice. Bars represent mean data
+/− SEM (n ≥ 12 animals per
genotype; age = 7 weeks). b
GCMS analysis for bile acid
composition in STAT3flox/flox and
STAT3Δhc mice. Note that the
relative level of UDCA is
elevated in STAT3Δhc mice
(1.806 ± 0.1683 % n = 12 for
STAT3flox/flox and
4.468 ± 0.3927 % n = 13 for
STAT3Δhc mice; p < 0.0001).Bars
represent mean data +/− SEM
(n ≥ 12 animals per genotype;





beta-muricholic acid, CA cholic
acid. c The bile flow was
measured by gall bladder
intubation in STAT3flox/flox and
STAT3Δhc mice. Bars represent
mean data +/− SEM (n ≥ 12
animals per genotype;




mice (n = 3 animals per
genotype). Formalin-fixed and
paraffin-embedded (FFPE) liver
tissues were stained for nuclei in
blue (DAPI), bile canaliculi in
green (DPPIV/CD26), periportal
hepatocytes in white (GS), and
hepatic sinusoids in red (DMs).
Scale = 100 μm (low
magnification), 30 μm (high
magnification)
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STAT3 protects hepatocytes from bile acid-induced
apoptosis
Primary hepatocytes were isolated and treated with bile
acids to investigate if elevated bile acid levels in
STAT3Δhc mice affect survival of STAT3-deficient hepa-
tocytes in a cell-intrinsic manner. Primary STAT3Δhc he-
patocytes were more sensitive to treatment with the bile
acid DCA (deoxycholic acid) than STAT3flox/flox hepato-
cytes (Fig. 2a), and activation of caspase-3 and caspase-8
was observed (Fig. 2b, c). Moreover, we employed loss of
the tumor suppressor protein p19ARF for hepatocyte im-
mortalization [19] to establish STAT3flox/flox p19ARF−/−
and STAT3Δhc p19ARF−/− hepatocyte cell lines that are
reminiscent to primary hepatocytes with respect to mor-
phology and hepatocyte-specific gene expression profiles
(data not shown). STAT3flox/flox p19ARF−/− and STAT3Δhc
p19ARF−/− immortalized hepatocytes were treated with
DCA, and apoptotic cell death was determined. Similar
to primary hepatocytes, cell viability of DCA-treated im-
mortalized STAT3-deficient hepatocytes was reduced
(Fig. 2d), and caspase 3 was activated (Fig. 2e). These
data demonstrate that STAT3 protects hepatocytes from
bile acid-induced death in a cell-intrinsic manner. We
have recently shown that expression of hepatoprotective
EGFR was reduced in STAT3Δhc and STAT3Δhc Mdr2−/−
mice. Therefore, we investigated if EGFR expression is
reduced in STAT3-deficient hepatocytes and can be in-
duced by IL-6 in a STAT3-dependent manner.
Immortalized STAT3flox/flox p19ARF−/− but not STAT3Δhc
p19ARF−/− hepatocytes displayed strong tyrosine-705
phosphorylation after IL-6 treatment which was main-
tained for 2 h (Fig. 2f). Expression of STAT3, which is
regulated by IL-6/pY-STAT3 signaling in a positive feed-
back loop [20], was induced in STAT3flox/flox p19ARF−/−
hepatocytes by IL-6 (Fig. 2g). In contrast, EGFR expres-
sion was not induced indicating that it is not regulated by
canonical IL-6/pY-STAT3 signaling (Fig. 2h). However,
EGFR expression was maintained at a constitutively low
level in STAT3Δhc p19ARF−/− hepatocytes (Fig. 2h). This
suggests that reduced expression of EGFR sensitizes
STAT3-deficient hepatocytes to bile acid-induced
apoptosis.
Fig. 2 STAT3 protects hepatocytes from bile acid-induced apoptosis. a
Phase contrast images of primary hepatocytes treated with indicated bile
acid (DCA) concentrations for 5 h. Representative images of three
biological replicates are shown. b, c Assays for active caspases 3 (b)
and 8 (c) in cultures of primary hepatocytes after 3 h DCA treatment.
Representative analyses of three biological replicates are shown. dMTT
assay demonstrating reduced viability of immortalized STAT3Δhc p19ARF
−/− hepatocytes after 3 h bile acid (DCA) treatment. A representative
analysis of four biological replicates is shown. e Assay for active
caspase 3 in cultures of immortalized hepatocytes after 3 h DCA
treatment. A representative analysis of two biological replicates is
shown. f Western blot analysis for tyrosine-705 phosphorylated pY-
STAT3 (upper images) in STAT3flox/flox p19ARF−/− and STAT3Δhc
p19ARF−/− hepatocytes after IL-6 treatment. The two pY-STAT3 bands
represent STAT3α and STAT3ß isoforms. Expression of ß-Actin (lower
images) was analyzed as loading control. g Real-time PCR analysis for
STAT3 expression in immortalized hepatocyte cultures after IL-6
treatment. Bars represent data +/− SEM of n ≥ 3 samples per genotype.
h Real-time PCR analysis for EGFR expression in immortalized
hepatocyte cultures after IL-6 treatment. Bars represent data +/− SEM
of n ≥ 3 samples per genotype
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STAT3 protects from cholestatic liver injury via regulation
of EGFR
We have shown that activated STAT3 and the closely related
STAT5 protein protect from cholestasis-induced liver injury
by partly overlapping molecular mechanisms that include reg-
ulation of EGFR [6, 21, 22]. Therefore, we employed a genet-
ic approach to evaluate if EGFR is a crucial hepatoprotective
factor in cholestatic liver injury and used mice with condition-
al deletion of EGFR in hepatocytes and cholangiocytes
(EGFRΔhc). Because recent evidence has suggested that
hepatocyte-specific AlfpCre mice display Cre effects could
lead to in vivo artifacts [23], we generated all possible
genotypes (wild-type, AlfpCre, AlfpCre EGFRflox/
f l ox = EGFRΔhc , AlfpCre Mdr2− /− and AlfpCre
EGFRflox/flox Mdr2−/− = EGFRΔhc Mdr2−/−) of mice
and performed biochemical and histopathological analy-
ses of liver injury and fibrosis. Importantly, EGFRΔhc
Mdr2−/− mice displayed aggravated liver fibrosis and
hepatic damage when compared with control mice.
Bilirubin levels were elevated in the serum of
EGFRΔhc Mdr2−/− mice (Fig. 3a, b) and they showed
signs of jaundice (Fig. 3c). The liver to body weight
ratio was increased in EGFRΔhc Mdr2−/− mice when
compared with Mdr2−/− mice (Fig. 3d). This was, how-
ever, partially due to the AlfpCre transgene because
AlfpCre Mdr2−/− mice without EGFR deletion also
displayed an increased liver to body weight ratio
(Fig. 3d). H&E staining of liver biopsies revealed prom-
inent periportal fibrosis and immune cell infiltration in
EGFRΔhc Mdr2−/− mice (Fig. 3e) which was reflected by
elevated serum levels of liver damage parameters
(Fig. 3f, g) and proliferation of bile ducts (Fig. 3h).
However, hepatocyte proliferation (Fig. 3i), apoptosis
(Fig. 3j) or numbers of macrophages and T cells in
the inflammatory infiltrates (Fig. 3k, l) were not
changed in EGFRΔhc Mdr2− /− mice. These data
Fig. 3 Mdr2−/− mice with liver-specific deletion of EGFR display
jaundice and aggravated liver damage. a The blood serum of EGFRΔhc
Mdr2−/−mice appeared yellow due to high bilirubin concentrations which
is indicative for jaundice. 1 EGFRflox/flox (wt), 2 AlfpCre, 3 AlfpCre
EGFRflox/flox (EGFRΔhc), 4 Mdr2−/−, 5 AlfpCre Mdr2−/−, 6 AlfpCre
EGFRflox/flox Mdr2−/− (EGFRΔhc Mdr2−/−). b Paws (arrowheads) and
teeth of EGFRΔhc Mdr2−/− mice appeared yellow due to jaundice. c
Measurement of bilirubin in the blood serum of indicated genotypes
(n ≥ 4). d Measurement of liver to body weight ratios in indicated
genotypes (n ≥ 5). e H&E-stained liver sections of indicated genotypes
showing severe periportal immune cell infiltration in EGFRΔhc Mdr2−/−
mice (arrowheads). Scale = 100 μm. f Measurement of alanine
aminotransferase (ALT) in the blood serum of indicated genotypes
(n ≥ 4). g Measurement of alkaline phosphatase (ALP) in the blood
serum of indicated genotypes (n ≥ 4). h IHC staining for Cytokeratin 19
on liver sections of indicated genotypes showing increased cholangiocyte
proliferation in periportal areas of EGFRΔhc Mdr2−/− mice (arrowheads).
Scale = 100 μm. i IHC staining for Ki67-positive hepatocytes
(arrowheads) on liver sections of indicated genotypes and quantitation.
Bars represent data +/− SEM of n ≥ 4 livers per genotype. Scale = 50 μm.
j Staining for apoptotic cells (arrowheads) on liver sections of indicated
genotypes and quantitation per liver area. Bars represent data +/− SEM of
n ≥ 4 livers per genotype. Scale = 50μm. k IHC staining for macrophages
(F4/80) or l T cells (CD3) and quantitation per infiltrated area. Bars
represent data +/− SEM of n ≥ 4 livers per genotype. Scale = 50 μm
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demonstrate that EGFR signaling protects from chole-
static liver injury in Mdr2−/− mice.
STAT3 protects from cholestatic liver fibrosis via
regulation of EGFR
Sirius-red staining for collagen deposition and biochemical
measurement of hydroxyproline levels, indicative for collagen
deposition, demonstrated aggravated liver fibrosis in
EGFRΔhc Mdr2−/− mice (Fig. 4a–c). AlfpCre Mdr2−/− mice
were comparable to Mdr2−/− mice demonstrating that aggra-
vated liver fibrosis is due to EGFR deletion but not AlfpCre
transgene expression (Fig. 4a–c). qPCR analysis demonstrat-
ed increased expression of several key genes implicated in
fibrosis in EGFRΔhc Mdr2−/− mice (Fig. 4d). These data dem-
onstrate that EGFR signaling protects from hepatic fibrosis in
Mdr2−/− mice.
Discussion
Hepatic fibrosis is due to chronic liver injury and partially
reversible which puts hepatoprotective factors for anti-
fibrotic therapies into the limelight. Genetically modified
mouse models for liver fibrosis [24, 25] have unraveled
effector molecules such as TGF-ß (transforming growth
factor beta) [26], PDGF-B [27] (platelet derived growth
factor b), PDGF-C (platelet derived growth factor c) [28],
or TIMP-1 (tissue inhibitor of metalloproteinase 1) [29],
but hepatoprotective factors are not well characterized.
We have recently shown that the cytokine IL-6 and the
cytokine-inducible transcription factor STAT3 protect
from cholestatic liver injury and fibrosis in the Mdr2−/−
mouse model for cholestatic liver disease [6]. Both, IL-6−/
− Mdr2−/− and STAT3Δhc Mdr2−/− mice showed aggravat-
ed liver damage and deposition of collagen in the
periportal areas. Gene expression profiling demonstrated
that genes for bile acid biosynthesis enzymes were upreg-
ulated whereas, EGFR was downregulated in STAT3Δhc
and STAT3Δhc Mdr2−/− mice. The mode how STAT3
represses bile acid biosynthesis genes and the implication
of known regulators such as FXR-α (farnesoid X receptor
alpha) or HNF-4 (hepatocyte nuclear factor 4) [30, 31]
has to be determined. We show that blunted repression
of bile acid biosynthesis genes at the mRNA levels is
reflected by a more than two-fold increase of total bile
acid concentrations in the bile of STAT3Δhc mice.
Mdr2−/− mice lack a phospholipid pump in the canalicular
Fig. 4 Severe liver fibrosis in EGFRΔhc Mdr2−/− mice. a Sirius-red
staining on liver sections of indicated genotypes showing increased
collagen deposition in periportal areas of EGFRΔhc Mdr2−/− mice
(arrowheads). Scale = 100 μm. b Quantitation of Sirius-red-stained
area on liver sections of indicated genotypes using histomorphometry
(n ≥ 4). c Collagen deposition was quantified using biochemical
determination of hydroxyproline levels in livers of indicated genotypes
(n ≥ 5). d qPCR for fibrosis markers in livers of indicated genotypes. Bars
represent data +/− SEM of n ≥ 4 livers per genotype. COL1 type I
collagen, COL3 type III collagen, TIMP1 tissue inhibitor of matrix
metalloproteinase 1, TIMP2 tissue inhibitor of matrix metalloproteinase
2, TGFB1 transforming growth factor beta 1; TGFB2 transforming
growth factor beta 2, MMP2 matrix metalloproteinase 2, CTGF
connective tissue growth factor
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membrane which prevents formation of mixed micelles
between bile acids and phospholipids. The free bile acids
are cytotoxic and damage cholangiocytes leading to mild
cholestasis and periportal fibrosis [32]. Therefore, elevat-
ed bile acid concentrations, as observed in STAT3Δhc
mice, are particularly harmful in an Mdr2-deficient genet-
ic background which contributes to aggravated liver dam-
age and fibrosis in STAT3Δhc Mdr2−/− mice.
Aggravated liver damage and formation of bile infarcts
have been observed in cholic acid-treated STAT3Δhc mice
but hepatocyte-intrinsic effects of STAT3 on cell survival
have not been addressed. Here, we show that primary and
immortalized hepatocytes, derived from STAT3Δhc mice,
were more sensitive to bile acid-induced apoptosis than
control hepatocytes. Reduced expression of EGFR, as ob-
served in hepatocytes of STAT3Δhc and STAT3Δhc Mdr2−/−
mice, was maintained in immortalized STAT3-deficient
hepatocytes. It has been shown that expression of a dom-
inant negative ERBB1 sensitized hepatocytes to bile acid-
induced apoptosis. A similar effect was observed after
pre-treatment of hepatocytes with the EGFR antagonist
Iressa [8–11]. Therefore, our results suggest that STAT3
prevents bile acid-induced apoptosis via positive regula-
tion of EGFR expression in a hepatocyte-intrinsic manner.
The functional consequence of EGFR signaling in cho-
lestatic liver disease was investigated in Mdr2−/− mice
l a ck ing EGFR expre s s i on in hepa tocy t e s and
cholangiocytes. Importantly, EGFRΔhc Mdr2−/− mice
phenocopied aggravated liver damage and fibrosis of
STAT3Δhc Mdr2−/− mice albeit liver damage and deposi-
tion of collagen was less severe. This was reflected by the
extended survival of EGFRΔhc Mdr2−/− mice when com-
pared to STAT3Δhc Mdr2−/− mice which died prematurely
due to severe jaundice [6]. STAT3 regulates additional
hepatoprotective factors such as IGF-1 (insulin like-
growth factor 1) [6] which might explain more severe
cholestatic liver damage in STAT3Δhc Mdr2−/− mice.
Compensatory hepatocyte proliferation and apoptosis
were not increased in EGFRΔhc Mdr2− /− mice .
Hepatocyte proliferation might be limited by ablation of
EGFR which is implicated in liver regeneration after par-
tial hepatectomy [14]. Moreover, bile acid-induced liver
damage in Mdr2−/− mice might be rather due to a necrotic
mechanism than apoptosis [6]. Our study suggests that
activation of EGFR signaling might represent a therapeu-
tic strategy to interfere with cholestatic liver injury and
fibrosis. It also emphasizes the need to monitor adverse
hepatic effects of EGFR inhibitors in cancer patients that
simultaneously suffer from cholestatic liver disease.
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